$0.45 EPS Expected for The Carlyle Group LP (CG); Aegerion Pharmaceuticals, Inc. (AEGR) Had 3 Bulls

July 17, 2017 - By Henry Gaston

Among 5 analysts covering Aegerion Pharmaceuticals (NASDAQ:AEGR), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. Aegerion Pharmaceuticals had 9 analyst reports since July 28, 2015 according to SRatingsIntel. The stock has “Hold” rating by Zacks on Friday, August 7. The firm has “Neutral” rating by Bank of America given on Wednesday, November 11. The firm has “Buy” rating by Guggenheim given on Monday, December 21. The stock has “Underperform” rating by Bank of America on Friday, February 12. The firm has “Buy” rating given on Tuesday, July 28 by Jefferies. See Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) latest ratings:

Analysts expect The Carlyle Group LP (NASDAQ:CG) to report $0.45 EPS on August, 2 before the open.They anticipate $0.10 EPS change or 28.57% from last quarter’s $0.35 EPS. CG’s profit would be $148.59 million giving it 11.24 P/E if the $0.45 EPS is correct. After having $1.09 EPS previously, The Carlyle Group LP’s analysts see -58.72% EPS growth. About 291,550 shares traded. The Carlyle Group LP (NASDAQ:CG) has risen 10.76% since July 17, 2016 and is uptrending. It has underperformed by 5.94% the S&P500.

Investors sentiment increased to 1.25 in Q4 2016. Its up 0.20, from 1.05 in 2016Q3. It is positive, as 16 investors sold The Carlyle Group LP shares while 28 reduced holdings. 18 funds opened positions while 37 raised stakes. 31.78 million shares or 10.10% more from 28.87 million shares in 2016Q3 were reported. Pinebridge Investments Lp holds 36,257 shares or 0.02% of its portfolio. Lmm Ltd Llc holds 0.13% or 200,000 shares. Cwm Limited Co holds 1,600 shares. Sandy Spring Financial Bank accumulated 3,760 shares. Walleye Trading Ltd owns 172,186 shares for 0.02% of their portfolio. Gp Hldg Ag stated it has 480,000 shares or 1.1% of all its holdings. Live Your Vision Ltd Com holds 0% in The Carlyle Group LP (NASDAQ:CG) or 100 shares. Hsbc Hldg Public Limited Com owns 0% invested in The Carlyle Group LP (NASDAQ:CG) for 35,563 shares. 1.81 million are owned by Goldman Sachs Group. Koch Indus owns 10,973 shares or 0.38% of their US portfolio. Moreover, Wells Fargo & Communication Mn has 0% invested in The Carlyle Group LP (NASDAQ:CG) for 343,069 shares. Susquehanna Gru Llp reported 60,067 shares. Thompson Siegel And Walmsley Limited Liability Co holds 0% in The Carlyle Group LP (NASDAQ:CG) or 400 shares. Peak6 Invs L P holds 0.01% of its portfolio in The Carlyle Group LP (NASDAQ:CG) for 103,454 shares. Brown Advisory stated it has 0% of its portfolio in The Carlyle Group LP (NASDAQ:CG).

Since May 3, 2017, it had 0 insider purchases, and 1 sale for $172,747 activity. On Wednesday, May 3 the insider Bentley Pamela L sold $172,747.

Among 12 analysts covering Carlyle (NASDAQ:CG), 6 have Buy rating, 0 Sell and 6 Hold. Therefore 50% are positive. Carlyle had 43 analyst reports since July 30, 2015 according to SRatingsIntel. Jefferies maintained the shares of CG in report on Tuesday, August 2 with “Hold” rating. The stock of The Carlyle Group LP (NASDAQ:CG) earned “Neutral” rating by Citigroup on Tuesday, December 15. As per Thursday, June 22, the company rating was maintained by Keefe Bruyette & Woods. The stock of The Carlyle Group LP (NASDAQ:CG) has “Hold” rating given on Thursday, June 16 by Deutsche Bank. The stock of The Carlyle Group LP (NASDAQ:CG) earned “Equal Weight” rating by Barclays Capital on Tuesday, August 11. As per Friday, October 14, the company rating was maintained by Wood. Barclays Capital maintained the shares of CG in report on Thursday, July 30 with “Equal Weight” rating. Goldman Sachs initiated the shares of CG in report on Tuesday, August 11 with “Neutral” rating. The rating was maintained by Deutsche Bank with “Buy” on Friday, September 18. Keefe Bruyette & Woods downgraded the shares of CG in report on Thursday, April 28 to “Market Perform” rating.

The Carlyle Group L.P. is a diversified multi-product global alternative asset management firm. The company has market cap of $6.68 billion. The Firm operates in four divisions: Corporate Private Equity , Real Assets, Global Market Strategies (GMS) and Investment Solutions. It has a 23.22 P/E ratio. Corporate Private Equity advises its buyout and growth capital funds, which pursue various corporate investments of different sizes and growth potentials.

It closed at $1.97 lastly. It is down 0.00% since July 17, 2016 and is . It has underperformed by 16.70% the S&P500.

Aegerion Pharmaceuticals, Inc. is a biopharmaceutical firm engaged in the development and commercialization of therapies for patients with debilitating rare diseases. The company has market cap of $56.69 million. It operates through pharmaceuticals segment. It currently has negative earnings. The Company’s products include lomitapide and metreleptin.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: